Table 1.
Clinical factors affecting overall survival and progression-free survival in patients with advanced pancreatic cancer.
| Variable | Patients (%) | Overall Survival | Progression-Free Survival | ||
|---|---|---|---|---|---|
| Median (Months) | p Value | Median (Months) | p Value | ||
| Age | |||||
| ≤65 years | 139 (59.9) | 10.580 | 0.114 | 6.110 | 0.254 |
| >65 years | 93 (40.1) | 8.310 | 7.000 | ||
| Gender | |||||
| Male | 149 (64.2) | 10.220 | 0.853 | 6.930 | 0.147 |
| Female | 83 (35.8) | 10.090 | 5.880 | ||
| Stage | |||||
| III | 60 (25.9) | 14.920 | 0.000 | 8.480 | 0.050 |
| IV | 172 (74.1) | 8.610 | 6.470 | ||
| Tumor location | |||||
| Head/neck/uncinate process | 93 (40.1) | 10.150 | 0.880 | 6.830 | 0.774 |
| Body/tail | 139 (59.9) | 10.120 | 6.110 | ||
| Tumor grade | |||||
| Well diff. | 15 (6.5) | 11.990 | 0.426 | 6.540 | 0.968 |
| Moderately diff. | 85 (36.6) | 11.070 | 6.800 | ||
| Poorly diff. | 43 (18.5) | 8.110 | 6.670 | ||
| Unknown | 89 (38.4) | 10.220 | 6.700 | ||
| Treatment | |||||
| CS + adj | 24 (10.3) | 25.590 | 0.000 | 9.430 | 0.039 |
| C/T | 172 (74.1) | 8.310 | 6.080 | ||
| C/T + local R/T | 36 (15.5) | 11.560 | 5.950 | ||
| CA19-9 | |||||
| ≤100 U/mL | 72 (31.0) | 12.160 | 0.019 | 6.970 | 0.067 |
| >100 U/ml | 160 (69.0) | 9.170 | 6.670 | ||
| BMI | |||||
| ≤22 kg/m2 | 116 (50.0) | 11.700 | 0.006 | 6.900 | 0.181 |
| >22 kg/m2 | 116 (50.0) | 8.310 | 5.880 | ||
| Hemoglobin | |||||
| ≤12 g/dL | 90 (38.8) | 8.280 | 0.002 | 5.950 | 0.258 |
| >12 g/dL | 142 (61.2) | 12.160 | 6.930 | ||
| Albumin | |||||
| ≤3.5 g/dL | 69 (29.7) | 5.720 | 0.000 | 7.260 | 0.859 |
| >3.5 g/dL | 163 (70.3) | 12.910 | 6.540 | ||
Abbreviations: diff., differentiation; CS, conversion surgery; adj, adjuvant chemotherapy; C/T, chemotherapy; R/T, radiotherapy; CA19-9, carbohydrate antigen 19-9; BMI, body mass index. The bold value indicates p < 0.05.